Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Tvardi Therapeutics (TVRD) Research & Development (2016 - 2025)

Tvardi Therapeutics' Research & Development history spans 13 years, with the latest figure at $5.5 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 36.17% to $5.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.2 million, a 63.67% decrease, with the full-year FY2025 number at $18.0 million, down 23.84% from a year prior.
  • Research & Development hit $5.5 million in Q4 2025 for Tvardi Therapeutics, up from $3.6 million in the prior quarter.
  • Over the last five years, Research & Development for TVRD hit a ceiling of $30.3 million in Q2 2023 and a floor of $319000.0 in Q1 2025.
  • Historically, Research & Development has averaged $17.0 million across 5 years, with a median of $20.6 million in 2022.
  • Biggest five-year swings in Research & Development: surged 59.15% in 2022 and later plummeted 98.55% in 2025.
  • Tracing TVRD's Research & Development over 5 years: stood at $22.8 million in 2021, then grew by 13.92% to $26.0 million in 2022, then rose by 9.25% to $28.4 million in 2023, then plummeted by 69.72% to $8.6 million in 2024, then tumbled by 36.17% to $5.5 million in 2025.
  • Business Quant data shows Research & Development for TVRD at $5.5 million in Q4 2025, $3.6 million in Q3 2025, and $5.8 million in Q2 2025.